TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16060241

Group type: EXPERIMENTAL
Intervention: Bilateral monitoring of blood flow velocity (BFV) in middle cerebral arteries using Multi Dop X; preoperative BWA on the affected side was 3.9 +/- 0.6 cm/s, intraoperative BWA increased to 7.7 +/- 1.1 cm/s (p < 0.05), postoperative BWA decreased to 4.2 +/- 0.8 cm/s.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bilateral monitoring of blood flow velocity (BFV) in middle cerebral arteries using Multi Dop X; preoperative BWA on the affected side was 9.6 +/- 1.1 cm/s (p < 0.05), intraoperative BWA increased to 12.1 +/- 2.6 cm/s, postoperative BWA decreased to 10.4 +/- 2.9 cm/s.
Number of subjects: 12
Study: 12445218

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) plus controlled-release chlorhexidine chip (CHX)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 20
Study: 10461805

Group type: EXPERIMENTAL
Intervention: ISI of 8 s
Number of subjects: 75

Group type: COMPARATOR
Intervention: ISI of 1 s
Number of subjects: 75

Group type: COMPARATOR
Intervention: ISI of 5 s
Number of subjects: 75
Study: 8765382

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Methohexital
Number of subjects: 50
Study: 1752060

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) co-treatment
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: COMPARATOR
Intervention: Gonadotrophin treatment alone
Number of subjects: 23
Study: 6126901

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Melperone (50 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (50 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Melperone (10 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Haloperidol (1 mg)
Number of subjects: 100
Study: 30761502

Group type: EXPERIMENTAL
Intervention: Compatible mapping of spoon tip defined as relevant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incompatible mapping of spoon handle defined as relevant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compatible mapping of chopstick handle defined as task relevant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional end of chopsticks defined as task relevant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colored red chopstick handles
Number of subjects: 0
Study: 28658139

Group type: EXPERIMENTAL
Intervention: Surgical guide template (group I)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Free-hand operation (group II)
Number of subjects: 8
Study: 27187097

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (AEP; n = 21)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Resistance and aerobic program (RAP; n = 22)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (n = 22)
Number of subjects: 65
Study: 24950987

Group type: EXPERIMENTAL
Intervention: Gefitinib (500 mg)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 450
Study: 22846686

Group type: EXPERIMENTAL
Intervention: Der p-SIT for 1 year
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (nonallergic controls)
Number of subjects: 68
Study: 19321512

Group type: EXPERIMENTAL
Intervention: Clinical Nurse Specialist (CNS) clinic
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional Junior Hospital Doctor (JHD) clinic
Number of subjects: 100
Study: 17967673

Group type: EXPERIMENTAL
Intervention: LCT propofol 0.1 mg/kg before induction
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: MCT/LCT propofol 0.1 mg/kg before induction
Number of subjects: 200

Group type: COMPARATOR
Intervention: LCT control (normal saline plus Intralipid)
Number of subjects: 200

Group type: COMPARATOR
Intervention: LCT/MCT control (normal saline plus Intralipid)
Number of subjects: 200
Study: 15111341

Group type: EXPERIMENTAL
Intervention: Oral ibandronate 20 mg once-daily for 96 weeks
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Oral ibandronate 50 mg once-daily for 96 weeks
Number of subjects: 435

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 435
Study: 11136277

Group type: EXPERIMENTAL
Intervention: Budesonide controlled ileal release (CIR) capsules, 9 mg orally in fasting state
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Budesonide controlled ileal release (CIR) capsules, 9 mg orally after a heavy breakfast
Number of subjects: 8

Group type: COMPARATOR
Intervention: Comparison of fasting vs postprandial conditions
Number of subjects: 8
Study: 9488587

Group type: EXPERIMENTAL
Intervention: 500 mg of oltipraz weekly for 8 weeks
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: 125 mg of oltipraz daily for 8 weeks
Number of subjects: 234
Study: 7541355

Group type: EXPERIMENTAL
Intervention: 40 mg flurbiprofen patch (n = 65)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Non‐medicated control (n = 66)
Number of subjects: 131
Study: 3170993

Group type: EXPERIMENTAL
Intervention: Azelastine 1 mg twice daily
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Azelastine 2 mg twice daily
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 30124572

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) (16 sessions)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Supportive‐expressive dynamic psychotherapy (SEDP) (18 sessions)
Number of subjects: 247
Study: 28209175

Group type: EXPERIMENTAL
Intervention: Strataderm® topical silicone gel only
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Pressure garment therapy only
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Combined Strataderm® topical silicone gel and pressure garment therapy
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 135
Study: 25451487

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting + surgical ventricular reconstruction
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting alone
Number of subjects: 1000
Study: 24119916

Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets (ITN)
Number of subjects: 8175

Group type: COMPARATOR
Intervention: Control group (no ITN)
Number of subjects: 8175
Study: 20442991

Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PV)
Number of subjects: 80
Study: 18086218

Group type: EXPERIMENTAL
Intervention: Lactobacillus F19 (LF19)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control (no LF19)
Number of subjects: 179
Study: 16814526

Group type: EXPERIMENTAL
Intervention: Functional Adaptations and Skills Training (FAST)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Attention-Control (AC)
Number of subjects: 240
Study: 14517705

Group type: EXPERIMENTAL
Intervention: Noscapine (oral administration)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no noscapine treatment)
Number of subjects: 10
Study: 11377130

Group type: EXPERIMENTAL
Intervention: Ferrous bis-glycinate chelate (5 mg of Fe daily per kg for 28 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: FeSO4 (5 mg of Fe daily per kg for 28 days)
Number of subjects: 40
Study: 9754192

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate (LE) 0.5%
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 203
Study: 7826580

Group type: EXPERIMENTAL
Intervention: Cellulose-based membranes (regenerated cellulose and cellulose acetate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synthetic membranes (polysulfone and polyacrilonitrile)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cellulose-based membranes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synthetic membranes
Number of subjects: 0
Study: 3073279

Group type: EXPERIMENTAL
Intervention: 20% azelaic acid
Number of subjects: 60

Group type: COMPARATOR
Intervention: 4% hydroquinone
Number of subjects: 60
Study: 30732579

Group type: EXPERIMENTAL
Intervention: Heparinoid moisturizer applied 2 weeks post-WBRT
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no moisturizer)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Prophylaxis group (moisturizer from the beginning of RT)
Number of subjects: 76
Study: 28357554

Group type: EXPERIMENTAL
Intervention: Repeat ETV
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Shunt post-ETV
Number of subjects: 81

Group type: COMPARATOR
Intervention: Primary shunt
Number of subjects: 81
Study: 24974219

Group type: EXPERIMENTAL
Intervention: Graphic health warnings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Text-only warning statement
Number of subjects: 0
Study: 22692120

Group type: EXPERIMENTAL
Intervention: Stable bench
Number of subjects: 16

Group type: COMPARATOR
Intervention: Balance cushion
Number of subjects: 16

Group type: COMPARATOR
Intervention: Swiss ball
Number of subjects: 16

Group type: COMPARATOR
Intervention: Swiss ball compared to balance cushion
Number of subjects: 16

Group type: COMPARATOR
Intervention: Stable bench compared to Swiss ball
Number of subjects: 16
Study: 22017930

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stents (BES)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Non-diabetic patients
Number of subjects: 25
Study: 19567547

Group type: EXPERIMENTAL
Intervention: MPC
Number of subjects: 170
Study: 16917623

Group type: EXPERIMENTAL
Intervention: Bromazepam 6 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 15316606

Group type: EXPERIMENTAL
Intervention: Irbesartan (150 mg orally, twice daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11165354

Group type: EXPERIMENTAL
Intervention: Unpredictable measurements
Number of subjects: 72

Group type: COMPARATOR
Intervention: Controllable measurements
Number of subjects: 72

Group type: COMPARATOR
Intervention: Predictable measurements
Number of subjects: 72
Study: 9295094

Group type: EXPERIMENTAL
Intervention: Migraineurs (Cys or Ser alleles at codon 23 of the 5-HT2C receptor gene)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Migraineurs with aura
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Migraineurs (men and women analyzed separately)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Controls (non-migraineurs)
Number of subjects: 242
Study: 8331120

Group type: EXPERIMENTAL
Intervention: Butel stem
Number of subjects: 56

Group type: COMPARATOR
Intervention: PCA design
Number of subjects: 56
Study: 31144836

Group type: EXPERIMENTAL
Intervention: MET + CBT + Exercise
Number of subjects: 37

Group type: COMPARATOR
Intervention: MET + CBT
Number of subjects: 37
Study: 31227537

Group type: EXPERIMENTAL
Intervention: Exercise intervention (twice a week 1‐hour aerobic and strength exercises supervised by a physiotherapist and twice a week 1‐hour Nordic or power walking)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (maintain habitual activity pattern during 6 months)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study: 28986667

Group type: EXPERIMENTAL
Intervention: PR oxycodone/naloxone
Number of subjects: 20

Group type: COMPARATOR
Intervention: PR oxycodone plus macrogol 3350
Number of subjects: 20
Study: 25917260

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia used in 51 (41%) patients
Number of subjects: 133

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 133
Study: 23767700

Group type: EXPERIMENTAL
Intervention: Descriptive norms
Number of subjects: 1607

Group type: EXPERIMENTAL
Intervention: Injunctive norms
Number of subjects: 1607
Study: 22393338

Group type: EXPERIMENTAL
Intervention: High-frequency chest compression
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure mask
Number of subjects: 34
Study: 18384087

Group type: EXPERIMENTAL
Intervention: Probiotics (VSL#3) for pouchitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probiotics (Escherichia coli Nissle 1917) for ulcerative colitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probiotics for Crohn's disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary ecological treatments for IBD
Number of subjects: 0
Study: 16649224

Group type: EXPERIMENTAL
Intervention: XPD *A haplotype
Number of subjects: 108
Study: 12826988

Group type: EXPERIMENTAL
Intervention: Temazepam 30 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Temazepam 15 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 75 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Valerian 400 mg and 800 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 11392165

Group type: EXPERIMENTAL
Intervention: Turner syndrome patients
Number of subjects: 37
Study: 8841951

Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1503379

Group type: EXPERIMENTAL
Intervention: Cefotaxime (3 g/day intravenously) + Rifaximin (1200 mg/day P.O.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cefotaxime (3 g/day intravenously)
Number of subjects: 30
Study: 6423365

Group type: EXPERIMENTAL
Intervention: Combined methimazole-lithium therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monotherapy of methimazole
Number of subjects: 0
Study: 31553468

Group type: EXPERIMENTAL
Intervention: Presence (interoception and attention module)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Affect (compassion module)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Perspective (perspective taking module)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Retest control (no training)
Number of subjects: 362
Study: 29381229

Group type: EXPERIMENTAL
Intervention: Codrituzumab exposure of ≥230 μg ml-1 and high CD16MESF level (>5.26 × 105 MESF at least)
Number of subjects: 181
Study: 26107538

Group type: EXPERIMENTAL
Intervention: Isolated lumbar extension exercise intervention (1×/week for 12 weeks, single set to momentary muscular failure using a load equal to 80% max tested torque)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nontraining control period
Number of subjects: 24
Study: 25142870

Group type: EXPERIMENTAL
Intervention: Physician-pharmacist collaborative management (PPCM)
Number of subjects: 126
Study: 22751603

Group type: EXPERIMENTAL
Intervention: golimumab 50 mg
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: golimumab 100 mg
Number of subjects: 405

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: golimumab (both doses)
Number of subjects: 405

Group type: COMPARATOR
Intervention: placebo (crossover to golimumab)
Number of subjects: 405
Study: 21104449

Group type: EXPERIMENTAL
Intervention: Diacylglycerol (DAG) supplementation
Number of subjects: 298

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 298
Study: 17495203

Group type: EXPERIMENTAL
Intervention: Clinic-based group
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Correspondence course
Number of subjects: 284

Group type: COMPARATOR
Intervention: Information-only control
Number of subjects: 284
Study: 15158303

Group type: EXPERIMENTAL
Intervention: Glutamine-enriched enteral nutrition (GLN)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Isocaloric, isonitrogenous enteral control (Con)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups (GLN and Con)
Number of subjects: 38
Study: 11668229

Group type: EXPERIMENTAL
Intervention: Intraperitoneal onlay mesh repair without cauterization (Group A)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Intraperitoneal onlay mesh repair with cauterization (Group B)
Number of subjects: 51
Study: 9520587

Group type: EXPERIMENTAL
Intervention: Information received from a physician
Number of subjects: 737

Group type: COMPARATOR
Intervention: Information received through other channels (e.g., weekly magazines)
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Higher level of education
Number of subjects: 737

Group type: COMPARATOR
Intervention: Lower level of education
Number of subjects: 737
Study: 7992904

Group type: EXPERIMENTAL
Intervention: Bispectral index
Number of subjects: 44

Group type: COMPARATOR
Intervention: Power spectral variables (95% spectral edge, median frequency, relative delta power)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Plasma propofol concentrations
Number of subjects: 44
Study: 2914153

Group type: EXPERIMENTAL
Intervention: iv placebo
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (8 subjects)
Number of subjects: 22
Study: 30974986

Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Insulin glargine U300
Number of subjects: 1600
Study: 27701901

Group type: EXPERIMENTAL
Intervention: Information about cognitive problems after chemotherapy with reassuring information
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Information about cognitive problems after chemotherapy without reassuring information
Number of subjects: 175

Group type: COMPARATOR
Intervention: No information about chemotherapy-related cognitive problems (control group)
Number of subjects: 175
Study: 25902515

Group type: EXPERIMENTAL
Intervention: High-quality foster care intervention (n = 48)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Institutional care (n = 43)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Foster care intervention (n = 48)
Number of subjects: 138
Study: 23572323

Group type: EXPERIMENTAL
Intervention: Gabapentin (300 mg after each haemodialysis session)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pregabalin (75 mg after each haemodialysis session)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (pretreatment values)
Number of subjects: 40
Study: 20978247

Group type: EXPERIMENTAL
Intervention: Neostigmine 50 μg/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg
Number of subjects: 50
Study: 19328860

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM)
Number of subjects: 368
Study: 16942566

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with a weekly dose of 200,000 SQ-U
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with a weekly dose of 24,000 SQ-U
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12749277

Group type: COMPARATOR
Intervention: Ranitidine alone
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Combination of ranitidine and ecabet
Number of subjects: 63
Study: 10811145

Group type: EXPERIMENTAL
Intervention: Estriol (E3) treatment (2 mg/day) for 30 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (CaCl2 without estriol)
Number of subjects: 24
Study: 8626978

Group type: EXPERIMENTAL
Intervention: Glycerin 10%
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Glycerin 20%
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Glycerin 30%
Number of subjects: 15

Group type: COMPARATOR
Intervention: Glycerin 0% (diluent)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Total glycerin dose (volume x concentration)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Glycerin (0% to 30%)
Number of subjects: 15
Study: 1445476

Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine 500 mg orally, 3 times a day for 180 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 3904818

Group type: EXPERIMENTAL
Intervention: Non-stress antepartum cardiotocography (revealed group)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Control group (withheld cardiotocograph recordings)
Number of subjects: 396
Study: 31094126

Group type: EXPERIMENTAL
Intervention: Oral progesterone (dydrogesterone) 10 mg twice daily
Number of subjects: 152

Group type: COMPARATOR
Intervention: Micronized progesterone (cyclogest pessary) 400 mg daily per rectal use
Number of subjects: 152
Study: 28716618

Group type: EXPERIMENTAL
Intervention: Intervention group viewed a telenovela about caregiving during a one-hour audiovisual seminar.
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group viewed a control video during a one-hour audiovisual seminar.
Number of subjects: 142
Study: 25050521

Group type: EXPERIMENTAL
Intervention: Infliximab and etanercept combination therapy
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 315

Group type: COMPARATOR
Intervention: Control group (joint pains without rheumatoid arthritis)
Number of subjects: 315
Study: 23490403

Group type: EXPERIMENTAL
Intervention: Stepwise withdrawal of NIV
Number of subjects: 60

Group type: COMPARATOR
Intervention: Immediate withdrawal of NIV
Number of subjects: 60
Study: 20886606

Group type: EXPERIMENTAL
Intervention: High-dose imatinib (800 mg/d) with pegylated interferon alpha-2b (0.5 μg/kg/wk) and GM-CSF (125 mg/m² 3× weekly)
Number of subjects: 94

Group type: COMPARATOR
Intervention: High-dose imatinib (800 mg/d) alone
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: High-dose imatinib (800 mg/d) with pegylated interferon alpha-2b and GM-CSF
Number of subjects: 94
Study: 19616196

Group type: EXPERIMENTAL
Intervention: Disgust mood induction
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Anxiety mood induction
Number of subjects: 120

Group type: COMPARATOR
Intervention: Neutral mood induction
Number of subjects: 120

Group type: COMPARATOR
Intervention: Happy mood induction
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Body-related interpretation bias
Number of subjects: 120
Study: 17855184

Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Teicoplanin
Number of subjects: 0
Study: 15150203

Group type: EXPERIMENTAL
Intervention: Pexelizumab (2.0 mg/kg bolus plus 0.05 mg/kg per hour for 24 hours; n = 1553)
Number of subjects: 3099

Group type: COMPARATOR
Intervention: Placebo (n = 1546)
Number of subjects: 3099

Group type: EXPERIMENTAL
Intervention: Pexelizumab (n = 1547)
Number of subjects: 3099

Group type: COMPARATOR
Intervention: Placebo (n = 1535)
Number of subjects: 3099
Study: 11212974

Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Lisinopril (10-20 mg)
Number of subjects: 166
Study: 9774932

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 0